PSP Research LLC acquired a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 44,223 shares of the company’s stock, valued at approximately $534,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Adage Capital Partners GP L.L.C. grew its position in Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after acquiring an additional 3,102,395 shares during the period. Perceptive Advisors LLC grew its position in Amylyx Pharmaceuticals by 0.4% during the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after acquiring an additional 28,017 shares during the period. TCG Crossover Management LLC grew its position in Amylyx Pharmaceuticals by 5.0% during the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after acquiring an additional 300,000 shares during the period. Vanguard Group Inc. grew its position in Amylyx Pharmaceuticals by 10.1% during the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock valued at $70,123,000 after acquiring an additional 531,162 shares during the period. Finally, Commodore Capital LP purchased a new stake in Amylyx Pharmaceuticals during the third quarter valued at about $55,386,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.
Amylyx Pharmaceuticals Stock Performance
NASDAQ:AMLX opened at $12.74 on Wednesday. Amylyx Pharmaceuticals, Inc. has a one year low of $4.64 and a one year high of $18.60. The business’s 50-day simple moving average is $15.24 and its 200 day simple moving average is $14.22. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -8.49 and a beta of -0.11.
Analyst Ratings Changes
AMLX has been the subject of several analyst reports. Bank of America upped their target price on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. Guggenheim upped their target price on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Mizuho upped their target price on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Finally, Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.00.
Get Our Latest Stock Report on AMLX
Amylyx Pharmaceuticals Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
Featured Articles
- Five stocks we like better than Amylyx Pharmaceuticals
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report).
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
